Literature DB >> 11185531

Prevalence of IgA antibodies to endomysium and tissue transglutaminase in primary biliary cirrhosis.

H R Gillett1, K Cauch-Dudek, E Jenny, E J Heathcote, H J Freeman.   

Abstract

The association between celiac disease and primary biliary cirrhosis has been described in several case reports and small screening studies, with varying prevalence rates. Stored sera from 378 patients with primary biliary cirrhosis were tested for immunoglobulin (Ig) A endomysium and tissue transglutaminase antibodies. Ten patients were positive for both antibodies (2.6%); five of these patients had had small bowel biopsies confirming celiac disease. A further 44 patients (11.6%) had raised titres of IgA tissue transglutaminase antibody but were negative for IgA endomysium antibody. The increased prevalence of celiac-related antibodies in patients with primary biliary cirrhosis suggests that the two conditions are associated, although the reason for the association remains unclear. Patients with primary biliary cirrhosis should be considered to be at high risk for celiac disease. Although liver biochemistry does not improve when these patients are fed a gluten-free diet, the complications of untreated celiac disease warrant the identification and treatment of the condition in this population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11185531     DOI: 10.1155/2000/934709

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  15 in total

Review 1.  Hepatobiliary and pancreatic disorders in celiac disease.

Authors:  Hugh James Freeman
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

Review 2.  The Liver and Celiac Disease.

Authors:  Alberto Rubio-Tapia; Joseph A Murray
Journal:  Clin Liver Dis       Date:  2019-03-01       Impact factor: 6.126

3.  Prevalence and clinical significance of immunoglobulin A antibodies against tissue transglutaminase in patients with diverse chronic liver diseases.

Authors:  Anastasios E Germenis; Efthalia E Yiannaki; Kalliopi Zachou; Violeta Roka; Sotirios Barbanis; Christos Liaskos; Kalliopi Adam; Andreas N Kapsoritakis; Spyros Potamianos; Georgios N Dalekos
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

Review 4.  Extraintestinal manifestations of celiac disease.

Authors:  Lincoln Hernandez; Peter H Green
Journal:  Curr Gastroenterol Rep       Date:  2006-10

5.  Low specificity of anti-tissue transglutaminase antibodies in patients with primary biliary cirrhosis.

Authors:  N Bizzaro; M Tampoia; D Villalta; S Platzgummer; M Liguori; R Tozzoli; E Tonutti
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

Review 6.  Pathogenesis and clinical significance of liver injury in celiac disease.

Authors:  Umberto Volta
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

Review 7.  Liver involvement in celiac disease.

Authors:  A Rubio-Tapia; J A Murray
Journal:  Minerva Med       Date:  2008-12       Impact factor: 4.806

8.  IgA and IgG tissue transglutaminase antibody prevalence and clinical significance in connective tissue diseases, inflammatory bowel disease, and primary biliary cirrhosis.

Authors:  N Bizzaro; D Villalta; E Tonutti; A Doria; M Tampoia; D Bassetti; R Tozzoli
Journal:  Dig Dis Sci       Date:  2003-12       Impact factor: 3.199

9.  Diagnosis of celiac disease.

Authors:  Shinjini Bhatnagar; Nitya Tandon
Journal:  Indian J Pediatr       Date:  2006-08       Impact factor: 5.319

10.  Clinical utility of serologic testing for celiac disease in ontario: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2010-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.